



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

26th July, 2021

To,

**The General Manager,
BSE Limited,**
Department of Corporate Services,
Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
“Exchange Plaza”,
Bandra – Kurla Complex,
Bandra (East),
Mumbai – 400 051

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting

We wish to inform you that pursuant to the provisions of Regulation 23 and Regulation 30 read of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audit Committee and the Board of Directors of the Company at their respective meetings held today have approved the following related party transactions/ matters, subject to obtaining shareholders' approval and all other applicable regulatory and statutory approvals:

- (a) Acknowledgment of the gratuitous transfer of the legal title and certain rights in respect of trademarks pertaining to 'Iodex' and 'Ostocalcium' brands in India, to the Company by Glaxo Group Limited;
- (b) Transfer of the trademarks 'pertaining to 'Iodex' and 'Ostocalcium' brands in India along with legal, economic, commercial and marketing rights of such brands and other associated assets to GlaxoSmithKline Asia Private Limited with respective values aggregating to Rs.1649.01 crores; and
- (c) Acquisition of assets and liabilities associated with the vaccines business of GlaxoSmithKline Asia Private Limited for a consideration of Rs.1.66 crores.

~~The meeting of the Board of Directors of the Company commenced at 5.00 p.m. and concluded at 08.15 p.m.~~

We request you to kindly take the above on record.

Thanking you,

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary